Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00077727 | A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia. | PHASE3 | COMPLETED | 107 | — | — | Mar 1, 2003 | Feb 1, 2005 | May 24, 2011 | - | — |
| Name | Type | Description |
|---|---|---|
| Extended-release galantamine hydrobromide | DRUG | - |
Inclusion Criteria: * Diagnosis of schizophrenia present for at least 1 year, and has not returned to his/her level of functioning before the disease, with a Brief Psychiatric Rating Scale score of 30 to 60 (inclusive), and cognitive impairment as determined by scores from neuropsychological tests ...